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Abstract: The biguanide drug metformin has been widely used for the treatment of type 2 diabetes,
and there is evidence supporting the anticancer effect of metformin despite some controversy.
Here, we report the growth inhibitory activity of metformin in the breast cancer (MCF-7) cells,
both in vitro and in vivo, and the associated metabolic changes. In particular, a decrease in a well-
known oncometabolite 2-hydroxyglutarate (2-HG) was discovered by a metabolomics approach. The
decrease in 2-HG by metformin was accompanied by the reduction in histone methylation, consistent
with the known tumorigenic mechanism of 2-HG. The relevance of 2-HG inhibition in breast cancer
was also supported by a higher level of 2-HG in human breast cancer tissues. Genetic knockdown
of PHGDH identified the PHGDH pathway as the producer of 2-HG in the MCF-7 cells that do not
carry isocitrate dehydrogenase 1 and 2 (IDH1/IDH2) mutations, the conventional producer of 2-HG.
We also showed that metformin’s inhibitory effect on the PHGDH-2HG axis may occur through the
regulation of the AMPK-MYC pathway. Overall, our results provide an explanation for the coherent
pathway from complex I inhibition to epigenetic changes for metformin’s anticancer effect.
Keywords: metformin; metabolomics; 2-HG; PHGDH; anticancer effect
1. Introduction
Metformin belongs to the biguanide-class drugs and has been used for decades for
the treatment of type 2 diabetes [1,2]. Its excellent safety profile, including a low incidence
of hypoglycemia, and low cost have made it the most frequently prescribed antidiabetic
drug in modern days [2,3] when more target-oriented antidiabetic drugs are available [4].
At the systemic level, metformin inhibits hepatic gluconeogenesis and glucose output [5]
and increases insulin sensitivity in the muscles [6]. The most proximal cellular target of
metformin is thought to be mitochondrial complex I, but the downstream effects seem to
be more complex [7,8]. The molecular mechanism of its antidiabetic effects has long been
thought to involve the activation of AMP-activated protein kinase (AMPK) [9], but other
studies, especially those involving animals lacking AMPK, strongly suggest the presence
of alternative mechanisms [10,11]. These may have to do with a decrease in cyclic AMP
(cAMP) synthesis, and the resulting inhibition of protein kinase A (PKA), a key enzyme in
glucagon signaling for the regulation of glycolysis and gluconeogenesis [11]. A retrospec-
tive study also reported reduced cancer incidences among diabetic patients treated with
metformin [12]. This initial result was followed by other studies supporting the beneficial
effect of metformin for colorectal and breast cancer patients with diabetes [13,14], although
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contradicting results have also been reported [15]. The effect of metformin on cancers
has been suggested to be mediated either indirectly through insulin or directly through
mammalian target of rapamycin (mTOR) modulation [7]. The indirect insulin-dependent
mechanism is based on insulin’s growth-promoting effect on tumor cells [16], and the direct
insulin-independent mechanism may occur both through AMPK dependently [17] or inde-
pendently through Rag-GTPase responses to energy status [18]. Still, the mechanistic details
and the effect of metformin on non-diabetic cancer patients are subjects of further studies.
In addition, the exact cancer patient population that will benefit most from the metformin
treatment is not well known. Many pre-clinical research and clinical trials are underway to
address these unknown aspects of metformin’s effect on cancer [19–21]. Phosphoglycerate
dehydrogenase (PHGDH) catalyzes the thermodynamically reversible conversion between
3-phosphohydroxypyruvate and 3-phosphoglycerate (3PG) [22]. This reaction is the first
step in serine biosynthesis from the glycolytic intermediate, 3PG. Several studies have
also implicated PHGDH in tumorigenesis in some cancers, such as breast cancer and
melanoma [23,24]. For breast cancer, PHGDH has been shown to be overexpressed mostly
in estrogen receptor-negative subtypes, including triple-negative subtypes. Still, serine syn-
thesis by PHGDH itself may not fully account for the tumorigenic roles of PHGDH, given
that serine supplementation to the PHGDH-knockdown cells did not rescue their growth
inhibition [23]. PHGDH was also shown to generate an oncometabolite 2-hydroxyglutarate
(2-HG) in PHGDH-amplified triple-negative breast cancer cells [25], suggesting that this
non-canonical activity of the enzyme may contribute to its tumorigenic role.
The oncogenic role of 2-HG was first suggested when a mutant isocitrate dehydro-
genase (IDH MT) in brain cancers was shown to produce it as a result of the neomorphic
activity [26]. The 2-HG has been shown to competitively inhibit alpha-ketoglutarate-
dependent dioxygenases including histone demethylases and TET methylcytosine hydrox-
ylases [27,28]. These inhibitions can cause a perturbation in the methylation status of the
nucleosome, which may contribute to the tumorigenic processes [29]. Although the 2-HG
production has been connected to the tumorigenesis by IDH mutations, several studies
also showed IDH mutation-independent production in leukemia and breast cancer sam-
ples [30,31]. Along with the above-mentioned 2-HG generation by PHGDH, these results
suggest that the inhibition of 2-HG production may be of therapeutic value in relevant
cancers with an IDH wildtype (WT) and a high level of 2-HG. Here, using metabolomic pro-
filing followed by mechanistic verification, we show that metformin suppresses the growth
of the MCF-7 estrogen receptor-positive breast cancer cell line through the inhibition of
2-HG production by PHGDH. Our results may prove a new mechanism for metformin’s
anticancer effect and help identify metformin-susceptible tumors.
2. Results
2.1. Xenograft Study on Metformin’s Cancer Prevention Effect
To investigate the relevance of metformin’s effect against breast cancer cells, we
established an in vivo xenograft mouse model bearing MCF-7 cells (Figure 1A). After
the oral administration of metformin to xenograft mouse, metformin-fed mice exhibited
significantly lower tumor volumes (Figure 1B) compared to the control group, with little
difference in body weights (Figure 1C).
Metformin was administrated daily at a 300 mg/Kg dose in drinking water. The
blood concentration of metformin could be about 24 to 31 mM, assuming the mouse total
blood volume to be 58.5 to 75 mL/Kg. This concentration is within the range of the
metformin concentration used in other studies [32–35]. The clinical dose for the metformin
administration is between 1500 mg/day to 2000 mg/day which roughly corresponds to
1.6 mM to 2.2 mM. Despite the relatively high dose of metformin administration here, no
serious problem with the change in mouse body weight was observed, which demonstrates
the relevance of the concentration used in our experiments.
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Figure 1. Mouse xenograft model of MCF-7 cells and metformin’s relevance in vivo. (A) MCF-7 cells 
were implanted subcutaneously into the right flank of BALB/c nude mice. Upper: control; lower: 
metformin treated. (B) The effect of 300 mg/Kg metformin daily administration on the growth of 
MCF-7 xenograft tumors. The upper panel shows sample tumors from 11 weeks post-metformin 
administration. The tumor size was measured once a week, and the average tumor tissue volume is 
represented in the lower panel with the mean ± standard deviations (n = 3). (C) Mouse body weight 
changes were determined every week after metformin administration. *, # statistically significant 
difference in tumor size. *: p < 0.05, #: p < 0.01. 
Metformin was administrated daily at a 300 mg/Kg dose in drinking water. The blood 
concentration of metformin could be about 24 to 31 mM, assuming the mouse total blood 
volume to be 58.5 to 75 mL/Kg. This concentration is within the range of the metformin 
concentration used in other studies [32–35]. The clinical dose for the metformin admin-
istration is between 1500 mg/day to 2000 mg/day which roughly corresponds to 1.6 mM 
to 2.2 mM. Despite the relatively high dose of metformin administration here, no serious 
problem with the change in mouse body weight was observed, which demonstrates the 
relevance of the concentration used in our experiments. 
2.2. Metformin’s Inhibitory Activity against Breast Cancer Cells 
There have been debates on metformin’s effectiveness in breast cancer treatment and 
prevention. To observe whether metformin exhibits inhibitory activity against breast can-
cer cells, we treated metformin to the MCF-7 ER-positive cancer cell line with MCF-10A 
as a benign control. The MTT assay showed that metformin significantly inhibited the 
growth of the MCF-7 cells with a much smaller effect on the MCF-10A cells (Figure 2A), 
and the same inhibitory effect was observed under a microscope (Figure 2B). The growth 
inhibition of MCF-7 cells by metformin was accompanied by other phenotypic changes 
such as changes in reactive oxygen species (Figure 2C) and glucose uptake (Figure 2D), 
and a decrease in ATP energy charge in the cell (Figure 2E). These results suggest that 
metformin has a differential inhibitory effect on MCF-7 cells, compared to normal cells, 
with metabolic implications. 
Figure 1. Mouse xenograft model of MCF-7 cells and metformin’s relevance in vivo. (A) MCF-7 cells were implanted
subcutane sly into the right flank of BALB/c nude mice. Upper: control; lower: metformin treated. (B) The effect of
300 mg/Kg metformin daily administration on the growth of MCF-7 xenograft tumors. The upper panel shows sample
tumors from 11 weeks post-metformin administration. The tumor size was measured once a week, and the average tumor
tissue volume is represented in the lower panel with the mean ± standard deviations (n = 3). (C) Mouse body weight
changes were determined every week after metformin administration. *, # statistically significant difference in tumor size.
*: p < 0.05, #: p < 0.01.
2.2. Metformin’s Inhibitory Activity against Breast Cancer Cells
There have been debates on metformin’s effectiveness in breast cancer treatment
and prevention. To observe whether metformin exhibits inhibitory activity against breast
cancer cells, we treated metformin to the MCF-7 ER-positive cancer cell line with MCF-10A
as a benign control. The MTT assay showed that metformin significantly inhibited the
growth of the MCF-7 cells with a much smaller effect on the MCF-10A cells (Figure 2A),
and the same inhibitory effect was observed under a icroscope (Figure 2B). The growth
inhibition of MCF-7 cells by metformin was accompanied by other phenotypic changes
such as changes in reactive oxygen species (Figure 2C) and glucose uptake (Figure 2D),
and a decrease in ATP energy charge in the cell (Figure 2E). These results suggest that
metformin has a differential inhibitory effe t on MCF-7 cells, com ared to n rmal cells,
with metabolic implications.
2.3. Metformin Induces Metabolomic Change and D creases 2-HG Level in MCF-7 Cells
We ext carried out m tabolomics studies to characterize the metabolic effects of
metformin on the inhibition of MCF-7 cell growth. NMR and LC/MS metabolomic data
were obtained from MCF-7 and MCF-10A cells with and without metformin treatment. We
identified the metabolites detected by the two methods, performed univariate analysis,
and listed significant ones in Table 1.




Figure 2. Metformin affects cancer cell growth and metabolic phenotypes. The final concentration 
of 20 mM metformin was treated to MCF-7 and MCF-10A cells for 2 days and the cell viability at 
each day was measured by a standard MTT assay (A) and microscope (B). (C) The change in ROS 
levels in MCF-7 cells after metformin treatment was measured using a fluorescent dye DCFH-DA. 
(D) The difference in glucose uptake by metformin treatment was compared by measuring glucose 
level in MCF-7 cell culture media using an NMR spectrometer. The relative amounts were normal-
ized against the 0 h point. (E) The change in energy charge of MCF-7 cells after metformin treatment 
was calculated with absolute concentrations of AMP, ADP, and ATP measured with LC/MS using 
the following equation: ([ATP] + 0.5 [ADP])/([ATP] + [ADP] + [AMP]). Ctrl: control group; Met: 
Metformin treated group. The data are from three independent experiments. The error bars repre-
sent the standard deviation. 
  
Figure 2. etfor in f ll ro th and metabolic phenotypes. The final concentration of
20 mM metformin was treated to MCF-7 and MCF-10A cells for 2 days and the cell viability at each
day was measured by a standard MTT assay (A) and microscope (B). (C) The change in ROS levels in
MCF-7 cells after metformin treatment was measured using a fluorescent dye DCFH-DA. (D) The
difference in glucose uptake by metformin treatment was compared by measuring glucose level
in MCF-7 cell culture media using an NMR spectrometer. The relative amounts were normalized
against the 0 h point. (E) The change in energy charge of MCF-7 cells after metformin treatment
was calculated with absolute concentrations of AMP, ADP, and ATP measured with LC/MS using
the following equati n: ([ATP] + 0.5 [ADP])/([ATP] + [ADP] + [AMP]). Ctrl: cont l group; M t:
Metformin treated group. The data are from three independent experiments. The error bars represent
the standard deviation.
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Table 1. Metabolite changes in MCF-7 cells after metformin treatment measured by an NMR and
LC/MS spectrometer.





















We further analyzed the NMR metabolomic data holistically using multivariate anal-
ysis. Principal component analysis (PCA) showed that the metformin treatment shifted
the overall metabolomic profiles of both MCF-7 and MCF-10A cells (Figure 3A), but the
change was more pronounced in MCF-7 cells. This was consistent with the larger effect of
metformin on the growth of MCF-7 than MCF-10A cells. Then, the orthogonal projections
to latent structure-discriminant analysis (OPLS-DA) was performed on MCF-7 cells to
investigate the metabolomic changes that contribute to the growth inhibition by metformin
treatment. Figure 3B shows that metformin treatment exhibited clearly distinguishable
metabolomic changes that may be attributable to several metabolites (Figure 3C). The
metformin-treated MCF-7 cells exhibited higher levels of AMP, GDP, and GSSG and lower
levels of glycolytic-TCA metabolites (G-6-P, F-6-P, and ATP; citrate and succinate) and
2-HG (Figure 3C). Of these, 2-HG was among the highest-ranking contributor, and its
~70% decrease upon metformin treatment caught our attention, as it is an established
oncometabolite that exists in high levels in a variety of cancers including glioma and
AML [36].
2.4. Metformin Changes Histone Methylation Status of MCF-7 Cells
With the link between metformin treatment and 2-HG modulation, we tested whether
the metformin-induced decrease in the 2-HG level causes changes to the epigenetic methy-
lation status. It has been known that the oncogenic mechanism of 2-HG generated by IDH
mutations involves the inhibition of alpha-ketoglutarate-dependent dioxygenases [29],
ultimately leading to the epigenetic methylation changes [27,37]. Therefore, we measured
histone methylation using anti-H3K4me3, H3K9me3, and H3K27me3 antibodies, and
the results showed reduced histone methylation in MCF-7 cells treated with metformin
(Figure 3D). Consequently, this increased histone demethylation by metformin seems to be
consistent with the decreased histone demethylation observed in IDH MT cells with high a
2-HG level [37]. On the other hand, we could not observe significant changes in the DNA
methylation status (Supplementary Figure S1). Overall, our results suggest that histone
epigenetic changes may be involved in the growth inhibitory effects of metformin through
a 2-HG reduction in MCF-7 cells.




Figure 3. Multivariate analysis on metabolomic changes, histone methylation status by metformin treatment in MCF-7 cells,
and the 2-HG level in breast cancer tissues from patients. (A,B) NMR metabolomic changes by metformin treatment were
analyzed by multivariate analysis. Black symbols: MCF-7; red symbols: MCF-10A; filled symbols: Control (Ctrl) group;
open symbols: Metformin (Met) treated group. (A) Principal component analysis (PCA) on metformin-treated and control
groups for MCF10a and MCF7 cells. (B) Orthogonal projections to latent structure-discriminant analysis (OPLS-DA) for
control and metformin-treated MCF-7 cells. (C) Multiple ROC curve analysis for the significance of contributing metabolites
using the quantitative LC/MS analysis. (D) The changes in the histone methylation status of MCF-7 cells were measured by
Western blot using H3K4me3, H3K9me3, and H3K27me3 antibodies after metformin treatment. The data are representative
of three independent experiments. (E) The 2-HG levels from paired normal (non-involved) and tumor tissues from breast
cancer patients were measured by LC/MS (n = 10 for each group).
2.5. The 2-HG Level Is Higher in Tumor Tissue Samples
Then, we tested the relevance of 2-HG and its reduction by metformin observed in
breast cancer cells with clinical samples. We measured the 2-HG level in the breast cancer
and the adjacent non-involved tissues (n = 10 for each group). The LC/MS analysis showed
that the 2-HG level in the cancer tissues was significantly higher than that in the normal
tissues (Figure 3E). Although this is a retrospective pilot result, it suggests that 2-HG
production may be involved in breast cancer and a target for a possible therapy. A larger-
scale test for the 2-HG level and the relevance of metformin treatment in a prospective
cohort are warranted.
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2.6. Metformin Reduces 2-HG Level through Downregulation of PHGDH
Next, we investigated how 2-HG is produced in MCF-7 cells. Many studies have
shown that 2-HG is highly elevated in glioma and AML cells harboring IDH mutations.
However, one study showed that about 40% of AML patients with a high 2-HG level have
an IDH WT genotype [30]. Therefore, we carried out DNA sequencing for IDH1 and IDH2
genes in MCF-7 cells, both of which turned out to be wildtype (Figure 4A). The results
suggest that 2-HG is not produced by IDH MT in MCF-7 cells and that its reduction by
metformin treatment does not arise from the inhibition of IDH MT. There was a previous
study suggesting that PHGDH can also produce 2-HG in triple-negative breast cancer
cells [25]. Therefore, we tested for the possibility that 2-HG reduction by metformin in
MCF-7 cells may occur through the drug’s effects on PHGDH. Western blot and real-time
PCR showed that both the PHGDH protein and mRNA levels are significantly reduced by
metformin treatment in MCF-7 cells (Figure 4B). To further prove that the reduction of 2-HG
by metformin treatment occurs through its modulation of PHGDH, we knocked down
PHGDH with siRNA and measured the 2-HG level using LC/MS. The siRNA treatment
lowered the PHGDH level (Supplementary Figure S2) and concomitantly inhibited the
2-HG generation (Figure 4C). These results strongly suggest that metformin’s effect on
2-HG occurs through its downregulation of PHGDH in MCF-7 cells.




Figure 4. Metformin inhibits 2-HG production by PHGDH in MCF-7 cells without IDH mutations. 
(A) DNA sequencing against IDH1 R132 and IDH2 R172 residues was performed using genomic 
DNA from MCF-7 cells. Codons for IDH1 R132 and IDH2 R172 are indicated in gray boxes as CGT 
and AGG encoding Arginine. (B) The PHGDH level after metformin treatment was measured for 
protein (left) and mRNA (right) by Western blot and real-time PCR, respectively. (C) The alteration 
of the 2-HG level by PHGDH siRNA was measured with LC/MS. The data are from five independ-
ent experiments. The error bars represent the standard deviation. 
2.7. AMPK-MYC Pathway is Implicated in the Regulation of PHGDH-2HG by Metformin 
Possible upstream mediators for metformin’s regulation of the PHGDH-2HG path-
way were also investigated. As previous studies revealed that PHGDH can be regulated 
by MYC [38,39] and that MYC is, in turn, down-regulated by AMPK activation [40,41], we 
tested the involvement of the AMPK-MYC pathway. Metformin treatment significantly 
activated AMPK, as judged by the phosphorylation of the enzyme (Figure 5A). At the 
same time, the MYC level was also significantly decreased by metformin (Figure 5B), con-
sistent with the previous report that MYC is degraded by activated AMPK [40,41]. We 
also knocked down MYC with siRNA and observed a decreased PHGDH level, which 
established the link between MYC and PHGDH (Figure 5C). These results implicate the 
AMPK-MYC pathway in the regulation of the PHGDH-2HG axis by metformin. 
Figure 4. Metformin inhibits 2-HG production by PHGDH in MCF-7 cells without IDH mutations.
(A) DNA sequencing against IDH1 R132 and IDH2 R172 residues was performed using genomic
DNA from MCF-7 cells. Codons for IDH1 R132 and IDH2 R172 are indicated in gray boxes as CGT
and A G encoding Argi ine. (B) The PHGDH level after metformin treatment was measured for
protein (left) and mRNA (right) by Western blot and real-ti e PCR, respectively. (C) The alteration of
the 2-HG level by PHGDH siRNA was measured with LC/MS. The data are from five independent
experiments. The error bars represent the standard deviation.
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2.7. AMPK-MYC Pathway Is Implicated in the Regulation of PHGDH-2HG by Metformin
Possible upstream mediators for metformin’s regulation of the PHGDH-2HG pathway
were also investigated. As previous studies revealed that PHGDH can be regulated by
MYC [38,39] and that MYC is, in turn, down-regulated by AMPK activation [40,41], we
tested the involvement of the AMPK-MYC pathway. Metformin treatment significantly
activated AMPK, as judged by the phosphorylation of the enzyme (Figure 5A). At the
same time, the MYC level was also significantly decreased by metformin (Figure 5B),
consistent with the previous report that MYC is degraded by activated AMPK [40,41]. We
also knocked down MYC with siRNA and observed a decreased PHGDH level, which
established the link between MYC and PHGDH (Figure 5C). These results implicate the
AMPK-MYC pathway in the regulation of the PHGDH-2HG axis by metformin.




Figure 5. Metformin inhibits PHGDH through the AMPK-MYC pathway. (A) Changes in (A) p-
AMPK and (B) c-MYC levels by metformin treatment were measured by Western blot. (C) The effect 
of c-MYC siRNA on PHGDH was estimated by Western blot. 
3. Discussion 
The effect of metformin on cancers is multifaceted, and may not be explained by sin-
gle-target effects [42]. At the patient level, many clinical studies are underway to deter-
mine whether metformin is effective for particular cancer prevention or treatment [20,43]. 
At the molecular level, multiple mechanisms have been proposed for its antitumor effect, 
such as the insulin-dependent, AMPK-dependent, or AMPK-independent pathways 
[7,44]. These not only reflect the complex nature of the effect of metformin, but may also 
suggest the inherent heterogeneity of different cancer tissues or even cancer cell lines. 
Therefore, in our pursuit of discovering the metabolic effect of metformin on breast can-
cers at a molecular level, we focused on a single ER-positive breast cancer cell line, MCF-
7, and tested the extrapolations of the results reported for the triple-negative breast can-
cers. The significant inhibition of the MCF-7 xenograft tumor by metformin in vivo con-
firms the relevance of our experimental system. Our results suggest that metformin inhib-
its the growth of MCF-7 cells, which seems to occur through metformin’s inhibitory effect 
on 2-HG production. We expanded PHGDH’s roles from producing 2-HG in triple-nega-
tive breast cancer cells [25], to the regulation of metformin’s growth inhibitory effect on 
ER-positive breast cancer cells. The effect of metformin on the histone methylation status 
is consistent with this suggestion. Interestingly, a related result was recently reported, 
showing an increased toxic effect of metformin on MCF-10A engineered to over-produce 
2-HG by mutant IDH1 R132H [45]. Overall, our study suggests a possible mechanistic 
linkage among metformin’s effect on cancer cells [46], PHGDH’s roles [25], and 2-HG pro-
duction in ER-positive breast cancer cells [31]. This is also consistent with the elevated 2-
HG level in breast carcinoma cell lines and its possible usage as a predictive marker for 
malignancy [47], and PHGDH’s roles in tumor formation and breast cancer metastasis 
[48]. The most plausible upstream pathway for the modulation of the PHGDH-2HG link 
by metformin appears to be metformin’s inhibition of c-Myc through activated AMPK 
[40,41]. It is well established that metformin activates AMPK by increasing the AMP level 
(low energy charge) through its inhibition of mitochondrial complex I, and it is one of the 
important upstream mechanisms for metformin’s antidiabetic and antitumor effect [49]. 
Consistently, we observed an increase in AMP and a decrease in ATP by metformin treat-
ment. In addition, we showed AMPK activation by metformin treatment. A recent study 
Figure 5. Metformin inhibits PHGDH through the AMPK-MYC pathway. (A) Changes in (A) p-AMPK and (B) c-MYC
levels by metformin treatment were measured by Western blot. (C) The effect of c-MYC siRNA on PHGDH was estimated
by Western blot.
3. Discussion
The effect of metformin on cancers is multifaceted, and may not be explained by single-
target effects [42]. At the patient level, many clinical studies are underway to determine
whether metformin is effective for particular cancer prevention or treatment [20,43]. At
the molecular level, multiple mechanisms have been proposed for its antitumor effect,
such as the insulin-dependent, AMPK-dependent, or AMPK-independent pathways [7,44].
These not only reflect the complex nature of the effect of metformin, but may also suggest
the inherent heterogeneity of different cancer tissues or even cancer cell lines. Therefore,
in our pursuit of discovering the metabolic effect of metformin on breast cancers at a
molecular level, we focused on a single ER-positive breast cancer cell line, MCF-7, and
tested the extrapolations of the results reported for the triple-negative breast cancers. The
significant inhibition of the MCF-7 xenograft tumor by metformin in vivo confirms the
relevance of our experimental system. Our results suggest that metformin inhibits the
growth of MCF-7 cells, which seems to occur through metformin’s inhibitory effect on 2-HG
production. We expanded PHGDH’s roles from produci g 2-HG in triple-negative breast
cancer cells [25], to the regulation of metformin’s growth inhibitory eff ct on ER-positive
breast cancer cells. Th effect of metformin o the histone methylation status is consistent
with this suggestion. Interestingly, a related resul was recently reported, showing an
increased toxic effect of me formin on MCF-10A engine r d to over-produce 2-HG by
mutant IDH1 R132H [45]. Overall, our study sugg sts a possible mechanistic linkage
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among metformin’s effect on cancer cells [46], PHGDH’s roles [25], and 2-HG production in
ER-positive breast cancer cells [31]. This is also consistent with the elevated 2-HG level in
breast carcinoma cell lines and its possible usage as a predictive marker for malignancy [47],
and PHGDH’s roles in tumor formation and breast cancer metastasis [48]. The most
plausible upstream pathway for the modulation of the PHGDH-2HG link by metformin
appears to be metformin’s inhibition of c-Myc through activated AMPK [40,41]. It is well
established that metformin activates AMPK by increasing the AMP level (low energy
charge) through its inhibition of mitochondrial complex I, and it is one of the important
upstream mechanisms for metformin’s antidiabetic and antitumor effect [7]. Consistently,
we observed an increase in AMP and a decrease in ATP by metformin treatment. In
addition, we showed AMPK activation by metformin treatment. A recent study reported
that MYC induces over-production of 2-HG and DNA epigenetic changes, which were
related to a poor prognosis in a subset of breast cancers [31]. In addition, glutaminase was
overexpressed in those tumors, which may contribute to 2-HG generation by supplying the
carbon source. Other studies also suggested that MYC can upregulate PHGDH [38]. Taken
together, our results showing the link between metformin and the PHGDH–2HG axis can
suggest a coherent mechanistic flow from complex I inhibition to epigenetic changes for
the growth suppression of the ER-positive MCF-7 cells by metformin. Although the 2-HG
production has been connected to the tumorigenesis by IDH mutations, recent studies also
showed 2-HG production to be independent of IDH mutations in leukemia and breast
cancer samples [49,50]. Along with the above-mentioned 2-HG generation by PHGDH, our
results suggest that the inhibition of 2-HG production may be a therapeutic strategy for
relevant breast cancers with an IDH WT and a high level of 2-HG.
It should be noted that not all previous results are in line with the proposed mecha-
nistic aspects of metformin’s anticancer effect. First, we observed changes in the histone
methylation status upon metformin treatment and the following 2-HG inhibition, but
could not observe concomitant DNA methylation changes. In comparison, DNA hyper-
methylation was observed, but the histone methylation status was not clear for 2-HG
over-producing breast cancer tumors [31]. In addition, leukemia cells from AML patients
with IDH1/2 mutations exhibited DNA hypermethylation patterns at global and specific
gene levels [51]. Still, it has been reported that histone methylation can induce cancer-
related epigenetic silencing independent of DNA methylation [52]. Furthermore, histone
hypermethylation was observed in IDH MT-transfected adipocytes with defective dif-
ferentiation, but DNA hypermethylation was absent in promotors for adipogenesis and
differentiation [37]. The same study also found that increased histone trimethylation was
observed from IDH MT glioma patient samples compared to IDH WT ones. Therefore,
the histone and DNA methylation status in 2-HG over-producing cancers could be either
enzyme (IDH, PHGDH, or else) or cancer tissue type (triple-negative vs. ER-positive or
leukemia vs. glioma or else)-dependent. Secondly, our result of PHGDH downregulation
by metformin was obtained using the MCF-7 cells, an ER-positive cell line without PHGDH
gene amplification or overexpression. In comparison, PHGDH overexpression has been
reported mainly in ER-negative, especially, triple-negative breast cancer cells [23,24]. In
addition, 2-HG over-production by PHGDH was first demonstrated in triple-negative
breast cancer cells [25]. Tests involving a wider range of cells and tumor types may prove
the relevance of the ER status in metformin’s effects.
Although metformin has been used extensively for diabetes, its effect can vary among
patients. Initially, an organic cation transporter 1 (OCT1) genetic status was proposed to
affect the antidiabetic responses [53], but later studies found that other transporters are
also important [54,55]. For metformin’s effects on cancers, many reports suggest reduced
cancer risk or survival benefits for diabetic breast or colon cancers [12–15,56–58]. However,
others pointed out biases in study designs [15] or an absence of the association between
metformin and mortality in a population-based study [59]. These uncertainties may be
related to the lack of understanding of the detailed mechanisms of metformin’s effects
and its targets. In this respect, a recent report is worth noting, where metformin exhibited
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survival benefits only in diabetic breast cancer patients with an ER/PR-positive and HER2-
positive status [60]. Therefore, defining a potential patient sub-population that can best
benefit from metformin may require further refinement. As we showed that metformin’s
anticancer effect is related to 2-HG inhibition by the downregulation of PHGDH and
c-MYC in ER-positive cells, a future clinical study may reveal whether the 2-HG and/or
PHGDH level can serve as a criterion for patient categorization for metformin’s response.
4. Materials and Methods
4.1. Reagents
Metformin (1,1-Dimethylbiguanide hydrochloride, D150959, Sigma), 2′,7′-Dichlo-
rofluorescin diacetate (DCF-DA, D6883, Sigma), β-Estradiol (E4389, Sigma), DMSO (D8418,
Sigma), thiazolyl blue tetrazolium bromide (M2128, Sigma), cholera toxin (C8052, Sigma),
EGF (E9644, Sigma), hydrocortisone (H0135, Sigma) and insulin solution (I0516, Sigma)
were obtained from Sigma-Aldrich (St. Louis, MO, USA). Metformin, EGF, and hydrocorti-
sone were dissolved in distilled water to make high concentration stock. Oligofectamine
(12252011) was purchased from Invitrogen (Waltham, MA, USA) and Matrigel Matrix
(354248, Corning, MA, USA) was obtained from the local distributor. Pierce™ ECL West-
ern Blotting Substrate (32109, Thermo Scientific, Waltham, MA, USA) and ImageQuant
LAS4000 (GE Healthcare Life Sciences, Pittsburgh, PA, USA) were used for western blot
analysis. DMEM (11995-074, Gibco), DMEM/F12 (11330-032, Gibco), FBS (16000-044,
Gibco), Trypsin-EDTA (25200-056, Gibco), penicillin streptomycin (15240-062, Gibco), and
MEM non-essential amino acids (11090-081, Gibco) were purchased from Gibco (Grand
Island, NY, USA). Antibodies for western blot were purchased from Cell Signaling tech-
nology (Danvers, MA, USA), Santa Cruz Biotechnology (Santa Cruz, CA, USA), Abcam
(Cambridge, MA, USA), and Millipore (Billerica, MA, USA); PHGDH antibody (13428, Cell
Signaling Technology), GAPDH antibody (sc-31915, Santa Cruz Biotechnology), β actin
(sc-47778, Santa Cruz Biotechnology), H3 total antibody (9715, Cell Signaling Technology),
H3K4me3 Antibody (A2357, Abcam), H3K9me3 Antibody (A2360, Abcam), H3K27me3
Antibody (EPR18607, Abcam), phosphor AMPK Antibody (ab133448, Abcam), c-MYC
Antibody (ab86356, Abcam).
4.2. Cell lines and Metformin Treatment
Breast cancer cell line MCF-7 and benign breast epithelial cell line MCF-10A were
from ATCC (Manassas, VA, USA). For routine maintenance of cells, MCF-7 and MCF-10A
cell lines were cultured in their respective media (MCF-7: DMEM including 10% FBS, 1%
MEM non-essential amino acids, and 1% penicillin streptomycin; MCF-10A: DMEM/F12
including final 10% FBS, 100 ng/mL cholera toxin, 20 ng/mL EGF, 500 ng/mL hydrocor-
tisone, and 10 µg/mL Insulin, and 1% penicillin streptomycin). For actual experiments,
MCF-7 cells grown in its own media were put through a media adaptation process for
24 h in the MCF-10A media to make the environments the same for both MCF-10A and
MCF-7 cells. Metformin was treated after the media adaptation at the final concentration
of 20 mmol/L metformin for 24 h. Cell viability after metformin treatment was measured
by the standard colorimetric MTT reduction assay. The MCF-7 cells were sequenced for the
mutations of IDH1 and IDH2 genes at Macrogen Inc. (Seoul, Korea).
4.3. Xenograft Mouse Model with MCF-7 Cells
Five-week-old female BALB/c nude mice (supplied from CLS Bio, Bucheon, Korea)
were used for the in vivo experiment. All animal housing and experiments were performed
under approved protocols from Seoul National University Institutional Animal Care and
Use Committees (approved number; SNU-160721-1-1). The mice were acclimatized for
one week before the beginning of the experiment. A mixture of 100 µL matrigel (Corning,
NY, USA) and 100 µL DPBS containing 1.5 × 107 MCF-7 cells was injected subcutaneously
on the right flank of the mice. With the injection of the cells, mice were fed 200 µg/mL
β-Estradiol (water soluble, Sigma-Aldrich, MO, USA) in drinking water for six weeks
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to facilitate the MCF-7 tumor growth [61]. Two weeks after the cell injection, mice were
divided into two groups and only one group was treated with metformin (300 mg/Kg body
weight daily in drinking water) by oral administration. The concentration of metformin
was calculated based on the water intake of the animals suggested from the Johns Hopkins
University Animal Care and Use Committee (1.5 mL/10 g body weight/day). Tumor
size was measured weekly with a caliper and calculated as follows: tumor size (mm3) =
[length (mm) × width (mm) × height (mm)] π/6.
4.4. Metabolomic Analysis and Metabolite Measurements
NMR and LC/MS metabolomics analysis, sample preparation, data acquisition, and
data processing were performed as described previously [49,50]. Energy charge was
calculated from the AMP, ADP, and ATP concentration measured with LC-MS using the
following equation: ([ATP] + 0.5 [ADP])/([ATP] + [ADP] + [AMP]). Glucose uptake was
assessed by measuring the glucose concentration in the media using 1D proton NMR [62].
The culture media was mixed with 4 times volume of methanol-acetonitrile mixture (5:3).
The sample was then centrifuged at 15,000 rpm for 20 min at 4 degrees and the supernatant
was dried using a vacuum concentrator. Dried samples were resuspended with 500 µL of
the NMR sample buffer (2 mM Na2HPO4 and 5 mM NaH2PO4 in D2O with 0.025% TSP
(trimethylsilylpropionic acid sodium salt-d4). The re-dissolved samples were transferred
to 5 mm NMR tubes and the glucose peak at 5.22 ppm on 1D proton NMR spectra was
integrated. At each time point, the glucose peak area was normalized against the 0 h point.
4.5. ROS Measurement
We detected the ROS changes using the fluorescence probes-based method (DCF-DA
method) which have been widely used by conjugation with the flow cytometry [63]. Cells
in 1 mL PBS were incubated with 3 µM of 2′-7′-Dichlorofluorescein diacetate (DCF-DA) in
light-protected microtubes for 30 min at 37 degrees and washed with PBS. Then, the cells
were resuspended with 1 mL of PBS and analyzed with the FACS Calibur® flow cytometer
with CellQuest Pro software (BD Biosciences, San Jose, CA, USA).
4.6. Quantitative Real-Time PCR and Western Blot Analysis
Total RNA extraction and cDNA synthesis were conducted with the Easy-Spin total RNA
extraction kit (iNtRON Biotechnology Inc., Seongnam, Korea) and the High-Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA) following the manu-
facturer’s protocols. Primers for PHGDH and GAPDH (Bioneer, Daejeon, Korea) were syn-
thesized with the following sequences: PHGDH sense 5′-AACTTCTTCCGCTCCCATTT–3′,
PHGDH antisense 5′–GTCATCAACGCAGCTGAGAA–3′, GAPDH sense 5′–GAGTCAAC
GGATTTGGTCGT–3′, GAPDH antisense 5′–TTGATTTTGGAGGGATCTCG–3′. For the
DNA amplification, iTAQ™ SYBR Green Supermix with ROX (Bio-Rad, Hercules, CA,
USA) and the synthesized cDNA were used according to the manufacturer’s instructions
on the Applied Biosystem’s 7500 fast system. Western blot experiments were performed
using routine procedures.
4.7. 2-HG Quantification from Human Breast Tissue Samples
We obtained 10 paired sets of human normal breast tissues and breast cancer tissues
from the Inha University Hospital Biobank (IUHB) at Incheon, Korea, and the Biobank of
Pusan National University Hospital at Pusan, Korea. Tissue samples were stored at -80 de-
grees until use. Frozen tissue samples were transferred into 1.5 mL microtubes containing
400 µL of methanol–chloroform solvent mixture (2:1) at 4 degrees. The samples were
homogenized with a pellet pestle motor (Kimble Chase®, Vineland, NJ, USA) on ice, and
200 µL of chloroform and 200 µL of distilled water were added. The homogenized samples
were vortexed for 30 sec and centrifuged at 15,000 rpm for 30 min at 4 degrees, and the
350 µL supernatant was dried with a vacuum concentrator. Dried samples were resus-
pended and applied to an LC/MS system for 2-HG level measurement. Pellets located in
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the middle phase after centrifugation were resuspended with 1 mL of 1 M urea buffer, and
the total protein concentrations were measured by a BCA assay for normalization.
4.8. DNA and Histone Methylation Analysis
For the DNA methylation analysis, total genomic DNA was extracted from har-
vested cells using the G-DEXTM IIc Genomic DNA Extraction Kit (iNtRON Biotechnology
Inc., Seongnam, Korea). The methylation status was measured using the MethylFlashTM
methylated DNA quantification kit (P-1035-48, EPIGENTEK, New York, NY, USA) and
MethylFlashTM hydroxymethylated DNA quantification kit (P-1036-48, EPIGENTEK, New
York, NY, USA) following the manufacturer’s instructions. Histone methylation was mea-
sured using Western blot analysis with an antibody against trimethylated H3K4, H3K9,
and H3K27.
4.9. PHGDH Knockdown with siRNA
For the siRNA treatment, 2 × 105 MCF-7 cells were seeded in a 6-well cell culture plate,
and 200 nmol/L of siRNA (Bioneer, Daejeon, Korea) and oligofectamine (Invitrogen, Grand
Island, NY, USA) mixture were added. After 24 h of culture, the media adaptation process was
carried out as mentioned above, followed by another 24 h-incubation with fresh MCF-10A
culture medium. The PHGDH siRNA (sense 5′-UCUAACCUUGGAGCUCACU(dTdT)-3′;
antisense 5′-AGUGAGCUCCAAGGUUAGA(dTdT)-3′, Bioneer, Daejeon, Korea) and the
negative control siRNA (Bioneer, Daejeon, Korea) were used in the experiment.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/metabo11080480/s1, Figure S1: DNA methylation status following metformin treatment in
MCF-7 cells, Figure S2: PHGDH knockdown by siRNA treatment.
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47. Smolková, K.; Dvořák, A.; Zelenka, J.; Vítek, L.; Ježek, P. Reductive carboxylation and 2-hydroxyglutarate formation by wild–type
IDH2 in breast carcinoma cells. Int. J. Biochem. Cell Biol. 2015. [CrossRef]
48. Samanta, D.; Park, Y.; Andrabi, S.A.; Shelton, L.M.; Gilkes, D.M.; Semenza, G.L. PHGDH Expression Is Required for Mitochondrial
Redox Homeostasis, Breast Cancer Stem Cell Maintenance, and Lung Metastasis. Cancer Res. 2016, 76, 4430–4442. [CrossRef]
49. Wen, H.; Xu, W.J.; Jin, X.; Oh, S.; Phan, C.H.D.; Song, J.; Lee, S.K.; Park, S. The roles of IP 3 receptor in energy metabolic pathways
and reactive oxygen species homeostasis revealed by metabolomic and biochemical studies. Biochim. Biophys. Acta (BBA) Mol.
Cell Res. 2015, 1853, 2937–2944. [CrossRef] [PubMed]
50. Wen, H.; Yang, H.J.; An, Y.J.; Kim, J.M.; Lee, D.H.; Jin, X.; Park, S.W.; Min, K.J.; Park, S. Enhanced phase II detoxification
contributes to beneficial effects of dietary restriction as revealed by multi-platform metabolomics studies. Mol. Cell. Proteom.
2013, 12, 575–586. [CrossRef]
51. Figueroa, M.E.; Abdel-Wahab, O.; Lu, C.; Ward, P.S.; Patel, J.; Shih, A.; Li, Y.; Bhagwat, N.; Vasanthakumar, A.; Fernandez, H.F.
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic
differentiation. Cancer Cell 2010, 18, 553–567. [CrossRef]
52. Kondo, Y.; Shen, L.; Cheng, A.S.; Ahmed, S.; Boumber, Y.; Charo, C.; Yamochi, T.; Urano, T.; Furukawa, K.; Kwabi-Addo, B.; et al.
Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat. Genet. 2008, 40,
741–750. [CrossRef] [PubMed]
53. Shu, Y.; Sheardown, S.A.; Brown, C.; Owen, R.P.; Zhang, S.; Castro, R.A.; Ianculescu, A.G.; Yue, L.; Lo, J.C.; Burchard, E.G.; et al.
Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J. Clin. Investig. 2007, 117, 1422–1431.
[CrossRef]
Metabolites 2021, 11, 480 15 of 15
54. Han, T.K.; Proctor, W.R.; Costales, C.L.; Cai, H.; Everett, R.S.; Thakker, D.R. Four cation-selective transporters contribute to
apical uptake and accumulation of metformin in Caco-2 cell monolayers. J. Pharmacol. Exp. Ther. 2015, 352, 519–528. [CrossRef]
[PubMed]
55. Chen, L.; Pawlikowski, B.; Schlessinger, A.; More, S.S.; Stryke, D.; Johns, S.J.; Portman, M.A.; Chen, E.; Ferrin, T.E.; Sali, A.; et al.
Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin. Pharmacogenet.
Genom. 2010, 20, 687–699. [CrossRef] [PubMed]
56. Algire, C.; Zakikhani, M.; Blouin, M.J.; Shuai, J.H.; Pollak, M. Metformin attenuates the stimulatory effect of a high-energy diet on
in vivo LLC1 carcinoma growth. Endocr. Relat. Cancer 2008, 15, 833–839. [CrossRef]
57. Dowling, R.J.; Goodwin, P.J.; Stambolic, V. Understanding the benefit of metformin use in cancer treatment. BMC Med. 2011, 9, 33.
[CrossRef]
58. Goodwin, P.J.; Pritchard, K.I.; Ennis, M.; Clemons, M.; Graham, M.; Fantus, I.G. Insulin-lowering effects of metformin in women
with early breast cancer. Clin. Breast Cancer 2008, 8, 501–505. [CrossRef]
59. Lega, I.C.; Austin, P.C.; Gruneir, A.; Goodwin, P.J.; Rochon, P.A.; Lipscombe, L.L. Association Between Metformin Therapy and
Mortality After Breast Cancer A population-based study. Diabetes Care 2013, 36, 3018–3026. [CrossRef] [PubMed]
60. Kim, H.J.; Kwon, H.; Lee, J.W.; Kim, H.J.; Lee, S.B.; Park, H.S.; Sohn, G.; Lee, Y.; Koh, B.S.; Yu, J.H.; et al. Metformin increases
survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes. Breast Cancer Res. 2015, 17, 64.
[CrossRef]
61. Dubois, V.; Dasnois, L.; Lebtahi, K.; Collot, F.; Heylen, N.; Havaux, N.; Fernandez, A.M.; Lobl, T.J.; Oliyai, C.; Nieder, M.; et al.
CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: In vivo toxicity, activity, and tissue distribution
confirm tumor cell selectivity. Cancer Res. 2002, 62, 2327–2331. [PubMed]
62. Wen, H.; Cho, H.R.; Yun, T.; Kim, H.; Park, C.K.; Lee, S.H.; Choi, S.H.; Park, S. Metabolomic comparison between cells over-
expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism. J. Neurochem. 2015, 132,
183–193. [CrossRef] [PubMed]
63. Gomes, A.; Fernandes, E.; Lima, J.L.F.C. Fluorescence probes used for detection of reactive oxygen species. J. Biochem. Biophys.
Methods 2005, 65, 45–80. [CrossRef] [PubMed]
